Lars Chistian Huber
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
Urwyler P, Leimbacher M, Charitos P, Moser S, Fehrman-Ekholm I, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci M, Huber L, Stüssi-Helbling M, Albrich W, Sendi P, Osthoff M. Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial. Front Immunol 2023; 14:1255292.
Oct 27, 2023Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
Oct 27, 2023Front Immunol 2023; 14:1255292
Urwyler Pascal, Leimbacher Marina, Charitos Panteleimon, Moser Stephan, Fehrman-Ekholm Ingela, Trendelenburg Marten, Thoma Reto, Sumer Johannes, Camacho-Ortiz Adrián, Bacci Marcelo R, Huber Lars Chistian, Stüssi-Helbling Melina, Albrich Werner, Sendi Parham, Osthoff Michael
The well-being of Swiss general internal medicine residents
Zumbrunn B, Vollenweider P, Reny J, Petignat P, Huber L, Henzen C, Hayoz D, Genné D, Brändle M, Beer J, Battegay E, Bassetti S, Ballmer P, Limacher A, Stalder O, Aujesky D. The well-being of Swiss general internal medicine residents. Swiss Med Wkly 2020; 150:w20255.
Jun 18, 2020The well-being of Swiss general internal medicine residents
Jun 18, 2020Swiss Med Wkly 2020; 150:w20255
Zumbrunn Brigitta, Vollenweider Peter, Reny Jean-Luc, Petignat Pierre-Auguste, Huber Lars Chistian, Henzen Christoph, Hayoz Daniel, Genné Daniel, Brändle Michael, Beer Jürg Hans, Battegay Edouard, Bassetti Stefano, Ballmer Peter E, Limacher Andreas, Stalder Odile, Aujesky Drahomir